Agoracom Blog Home

Archive for the ‘Tetra Bio-Pharma Inc.’ Category

Tetra Bio-Pharma $TBP.ca to engage in co-development and distribution partnership with major healthcare specialty distributor

Posted by AGORACOM-JC at 8:19 AM on Wednesday, September 20th, 2017

Tbp large new

  • Announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry
  • Privately-owned partner has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals
  • First product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018
  • Tetra and its partner will be tapping into the overall Over-The-Counter topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis

OTTAWA, ONTARIO–(Sept. 20, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry.

This privately-owned partner, which asked to remain unnamed for the time being, has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to over 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners, including the USA.

Tetra and its partner are working together to develop a new line of products, leveraging Tetra’s clinical and product development expertise. The first product will be launched in Q1 2018 with subsequent products already in development for the remainder of 2018. Tetra and its partner will be tapping into the overall Over-The-Counter (OTC) topical analgesics market of more than $300 million in sales in Canada, with the US market reaching over $2.9 billion, according to an IMS analysis. Both companies are expecting to grab a share if the specialized OTC topical analgesics market in a short period of time and could see sales generated from this distribution channel reaching $3 million for Canada in the 1st year. Since the initial launch phase will be focused on the Canadian market, further guidance will be provided as Tetra’s partner gets ready to launch in the US.

« We’re excited to enter this specialized market as there is a significant need for our clinical expertise in product development. This partnership opens a new distribution channel for our pharmaceutical retail division not only in Canada, but also worldwide through their active partners in the US and Europe. Tetra remains committed and is actively developing partnerships to generate a significant revenue stream. This partnership demonstrates our team’s focus and dedication in accelerating our commercialization strategy towards selling a specialized line of products in our pharmaceutical retail business, » comments Bernard Fortier, CEO of Tetra Bio-Pharma.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra has three core expertise: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based drugs.

More information at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Anne-Sophie Courtois
Vice-President Marketing & Communication
1 (514) 360-8040 Ext. 210
Anne-sophie.courtois@tetrabiopharma.com
www.tetrabiopharma.com

Invested in #MMJ stocks like Cannagrow $CGRW ? Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

Posted by AGORACOM-JC at 12:36 PM on Thursday, September 14th, 2017

Tbp large new

TBP: TSX-V

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Interested AeroGrow $AERO ? Check out Tetra Bio-Pharma $TBP.ca $TBPMF

Posted by AGORACOM-JC at 11:47 AM on Tuesday, August 29th, 2017

Tbp large new

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Invested in Cannagrow $CGRW.ca ? Check out Tetra Bio-Pharma $TBP.ca

Posted by AGORACOM-JC at 9:46 AM on Monday, August 28th, 2017

Tbp large new

Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Tetra Bio-Pharma $TBP.ca Receives Approval to List on the #TSX-V #MMJ

Posted by AGORACOM-JC at 8:09 AM on Wednesday, August 16th, 2017

Tbp large new

  • Approved for trading on the TSX Venture Exchange Under TBP:TSX-V

OTTAWA, ONTARIO–(Aug. 16, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). Tetra’s shares will commence trading on the TSX Venture on the opening of markets on Wednesday, August 16, 2017, under the symbol “TBP”.

“We are pleased to announce that the TSX Venture Exchange has accepted our application for listing,” said Bernard Fortier, CEO of Tetra Bio-Pharma Inc. “We believe this move will enhance trading liquidity and continue to increase market adoption of our business model, thereby enhancing shareholder value. We look forward to aggressively executing our business plan as we build the leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”

Mr. Fortier further added, “We would like to thank the CSE for all their support and commitment to Tetra these past years in our evolution as an organization.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (TSX VENTURE:TBP) (OTCQB: TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO $TBP.ca

Posted by AGORACOM-JC at 9:09 AM on Monday, July 24th, 2017

Tbp large new

  • Appointmented of Bernard Fortier to the position of Chief Executive Officer
  • Over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields

OTTAWA, ONTARIO–(July 24, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors. Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a Board member.

Bernard Fortier is a graduate from the MBA program at l’école des Hautes Études Commerciales (HEC) in Montreal, with over 20 years of international experience in management and business development in the biopharma, specialized medical nutrition and medical fields.

Mr. Fortier spent 5 years in the USA working in the therapy and rehabilitation market, having graduated from the physiotherapy program at Laval University. His experience in the USA enabled him to work on business development and management early in his career. After completing his MBA in 2001, he joined the pharmaceutical industry with a biotechnology company. He spent 8 years in various key commercial roles at Serono Canada (now EMD Serono) in the Multiple Sclerosis field, including National Sales Manager for the Neurology business unit.

In 2010, Bernard became the Country Manager for Nutricia Canada, the specialized medical nutrition division of Groupe Danone. He was recruited in 2012 to launch a new pharmaceutical company called Orimed Pharma. Through licensing deals and internal product development, the company’s portfolio grew from 3 to 10 products within 4 years.

“I am very pleased to welcome Bernard to the team as our new CEO as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Bernard is an experienced leader and executive with proven skills in leadership, strategy and execution, as well as business development and negotiation. Mr. Fortier has a clear mandate from the Board, to grow revenue and build Tetra as a global leader in pharmaceutical cannabis. Going forward, we will be placing considerable efforts in expanding Tetra in the U.S. market.”

Corporate Update:

Mr. Andre Rancourt, previous interim CEO was elected to the position as Chairman of the Board of Directors. The Board has mandated Mr. Rancourt to continue taking an active and dynamic role as he demonstrated as Interim CEO. Mr. Rancourt will be responsible for the administration, overall corporate governance and financing of the corporation.

Mr. Andre Audet will step down as Chairman of the Board of Directors but will continue to serve as a member of the Board. The Corporation wishes to thank Mr. Audet for all his efforts in working to grow Tetra where it is today and looks forward to his continued participation in building Tetra as a global leader in pharmaceutical cannabis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
www.tetrabiopharma.com

Tetra Bio-Pharma Signs LOI with Constance Therapeutics TBP.ca

Posted by AGORACOM-JC at 9:52 AM on Wednesday, July 19th, 2017

Tbp large new

  • Signed a Letter of Intent (LOI) with Constance Therapeutics,
  • Clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products
  • AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market

OTTAWA, ONTARIO–(July 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.

The AgroTek Health subsidiary of Tetra will work with Constance Therapeutics to bring these products to the Canadian medical marijuana market under a commercial license agreement. “Over the coming months, the corporation will be focusing its energy on generating revenues while becoming an important player in the medical marijuana market,” commented Mr. Andre Rancourt, CEO of Tetra. “The products developed by Constance Therapeutics are exactly what the corporation is looking for in terms of novel cannabis products developed for patients. The approach used by Constance Therapeutics is exactly the type of business model that Tetra is implementing to bring medical marijuana products to patients.”

“Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, auto-immune, chronic pain, neurodegenerative diseases, and other out-of-option patients,” commented Constance Finley, Founder and CEO of Constance Therapeutics, Inc. She added, “over the years, research demonstrates that cannabinoids including specific terpenes, reduce and inhibit tumor growth in various animal models. Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as Glioma, compared to controls.”

Tetra will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products initially focusing on their use in treating patients with brain cancer. Tetra will work closely with oncologists to evaluate the therapeutic benefit of these products according to pharmaceutical standards.

These products are currently available to patients living in California, USA and are consumed sublingually and through vaporization. As part of its mission to bring effective cannabinoid-based products to cancer patients, Tetra will be working in partnership with Constance Therapeutics to investigate the potential efficacy in a clinical trial.

About Constance Therapeutics:

Constance Therapeutics, Inc. is a manufacturer and licensor of cannabis products designed to enable medical professionals offer their patients a broader array of treatment options. The products fill the gap between traditional pharmaceuticals and commonplace cannabis products through manufacturing protocols using highly controlled, quantitatively-defined and patented processes. The products are third-party tested in the industry’s most respected laboratories. Since 2008, the company has employed stringent, science-based processes and standards to ensure the highest quality and consistency. Headquartered in San Francisco, California, Constance Therapeutics’ products have historically been accessed exclusively for therapeutic use and could only be purchased by registered California patients, in keeping with Proposition 215, and California Senate Bill 420. For further information, visit: www.constancetherapeutics.com.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders’ Meeting & Provides a Corporate Update $TBP.ca

Posted by AGORACOM-JC at 5:30 PM on Tuesday, July 11th, 2017

Tbp large new

  • Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
  • The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline

OTTAWA, ONTARIO–(July 11, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders’ meeting.

Resolution For Against Withheld Spoiled No Vote % For % Against % Withheld
André Rancourt 18,439,319 0 19,449 0 443,314 99.89 % 0.00 % 0.11 %
André D. Audet 18,439,304 0 19,464 0 443,314 99.89 % 0.00 % 0.11 %
Robert Brouillette 18,456,735 0 2,033 0 443,314 99.99 % 0.00 % 0.01 %
Dr. W.M. (Bill) Cheliak 18,456,750 0 2,018 0 443,314 99.99 % 0.00 % 0.01 %
Appointment of McGovern, Hurley, Cunningham, LLP, as auditors of the Corporation and to authorize the directors to fix the remuneration to be paid to the auditors. 18,884,340 0 17,742 0 0 99.91 % 0.00 % 0.09 %
The amendment of the Stock Option Plan from fixed to rolling. 18,282,545 176,222 0 0 443,315 99.05 % 0.95 % 0.00 %

At the meeting, some key corporate highlights which were discussed, included:

  • Tetra is the only pharmaceutical company to have clinical studies for smoked marijuana;
  • The Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001. Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • The initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than what we expected for sales. We are now putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control. We will look at launching PPP001 using the ACMPR license by the end of summer. See press release announced April 17, 2017 for further information;
  • We are looking to start the Phase II clinical trials for PPP002 – Dronabinol XL in the next month; and
  • Investor outreach will be principally focused on the U.S. market going forward looking at targeting healthcare funds to potentially invest in Tetra. Communications strategy is to make very clear that Tetra is not a marijuana company but a pharmaceutical company.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals $TBP.ca

Posted by AGORACOM-JC at 9:05 AM on Wednesday, July 5th, 2017

Tbp large

  • Strengthened its position on bringing marijuana to patients in the form of a prescription drug
  • Has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017

OTTAWA, ONTARIO–(July 5, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017. According to this report, Tetra is the only company developing dried marijuana as a drug.

One in five Canadians will live with pain in their lifetime and one in two will be affected by cancer. Canadian courts have ruled in favor of patients wanting access to marijuana for relief. In response to these decisions, the Canadian government has implemented the Access to Cannabis for Medical Purposes Regulations (ACMPR) to help bring marijuana to patients. Canada’s Prime Minister has been very favorable in bringing marijuana to patients but it will be up to corporations to step in and adhere to the Canadian Food and Drug regulations to bring marijuana medications to patients. Tetra is a world leader in the drug development field of cannabis-based medications and is paving the road to become the first company to commercialize a dried marijuana product as a drug in North America.

“Canadian’s are entitled to access to marijuana to treat their pain or its co-morbidities. It is not a question of social standing or a judgement if the act of ‘smoking’ is acceptable for patients. It is a fundamental right to have access to a botanical drug that can effectively allow patients to have a better quality of life,” commented Dr. Guy Chamberland, CSO of Tetra Bio-Pharma. “There is sufficient evidence suggesting that smoking marijuana is an adequate medication to help relieve pain and improve a patient’s well-being. Both of these are important aspects to offering effective therapies to patients. The challenge has been addressing quality and safety issues to meet the standards of a drug.”

Over the years our society has inherited an image that ‘smoking’ or ‘vaporizing’ is not associated with a healthy approach to health care. According to the expert committee on the Health Effects of Marijuana (National Academies Press, 2017), ‘smoking cannabis does not increase the risk for certain cancers (i.e., lung, head and neck)’. In addition, cancer patients typically consume an amount of dried marijuana per day, in dry weight, that is less than 1 tobacco cigarette, without the paper, per day. The significantly reduced amount of smoke per day is one of the explanations supporting that smoking marijuana does not increase the risk for these cancers. That said, these are effective routes of delivering a complex botanical medication. “Society has to focus on caring for all patients living with pain not just those that want a different dosage form,” commented Dr. Chamberland. He added, “In fact our challenge is to characterize the safety and efficacy of this therapy, ensure lot-to-lot quality, provide adequate risk information to health professionals, demonstrate the safety and efficacy so that physicians can adequately assess the potential efficacy and safety for their patient, and actively pursue more tolerable dosage forms to offer these innovative cannabis therapies to patients. In the end, a patient’s desire to smoke marijuana for relief has to be defended by Canadian courts and politicians. We live in a democratic society and we have to care for everyone.”

“Tetra undertook the development of PPP001 as a first prescription marijuana drug. The company is preparing its phase 3 trial in cancer patients and will assess the safety and efficacy using both the titanium pipe and vaporizer delivery systems. From Day 1, Tetra was dedicated to characterizing the safety and tolerability of consuming medical marijuana by smoking. Tetra also adopted the firm position of working transparently with regulators because the corporation believed it is important to bring marijuana, as traditionally used, to patients. Tetra will continue to work with provincial and federal governments, including physician and pharmacist professional corporations, to help address issues associated with the development and commercialization of a first prescription medical marijuana drug.”

“Tetra already works closely with Health Canada through the regulatory processes in place for the development of drugs and controlled substances,” commented Dr. Chamberland. He added that, “Tetra was working closely with the province of New Brunswick whom from Day 1 was very active in preparing for the eventual legalization of marijuana in Canada. Tetra is working with physician and pharmacist professional associations/corporations and will be working closely with these health professionals as the company prepares for its Phase 3 trial and the eventual commercialization of the first dried marijuana drug.”

“Tetra has performed safety, pharmacokinetic and cognitive function studies in healthy volunteers. The corporation has characterized the safety of consuming marijuana and understands what the potential risks are to consumers and patients. This information will be made available by Tetra to Health Canada and to other government departments on request. We believe that this safety data provides a clear and accurate picture of what happens to people that smoke marijuana recreationally,” commented Dr. Chamberland. “We believe it is our responsibility to provide this information to regulators to help pave the road for the Trudeau government’s legalization.”

In addition, Tetra will use its clinical knowledge from its Phase 1 and Safety clinical studies to implement effective and secure patient care programs. This includes working with independent professional organizations to transfer its clinical risk information and ensure that these groups provide continued medical education to their health professionals. Dr. Chamberland commented, “Launching the first dried marijuana drug in Canada brings a responsibility of ensuring that all safety risks are communicated to health professionals to ensure the well-being of consumers. No body wants another fentanyl-type crisis; all we want is for patients to obtain relief and an improved quality of life when consuming marijuana that is of the same quality as any other prescription medication.”

“Tetra will be actively pursuing the development and commercialization of PPP001 to remain a world leader in the field of cannabis medicine,” commented Andre Rancourt, CEO of Tetra Bio-Pharma. “We are dedicated to working with distributors and pharmaceutical companies interested in bringing medical marijuana as a prescription drug around the world. We are focusing on bringing to patients what the Supreme Court of Canada ruled was their right: access to marijuana.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market $TPB.ca

Posted by AGORACOM-JC at 8:27 AM on Wednesday, June 28th, 2017

Tbp large

  • Commercializing novel cannabinoid based formulations for the treatment of pet conditions
  • Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities

OTTAWA, ONTARIO–(June 28, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.

Over the last year, Tetra demonstrated its leadership in the development of human prescription cannabinoid drugs and will use the same strategy to become a leader in the field of veterinary cannabinoid drug products. Tetra will adopt a similar regulatory approach of transparency and collaboration with the veterinary drug authorities. In fact, Tetra is well suited to tackle the veterinary drug market since the ACMPR was created to allow human patient’s access to medical marijuana and does not provide any measures to allow testing of cannabis or cannabis derived products in pets.

According to a USA Federal Trade Commission May 2015 report, in 2014, Americans spent approximately $58 billion on their pets, including medications. This number more than doubled since 2001. This market is expected to enjoy excellent growth over the next decade as new therapies provide better and more tolerable treatment for pets. According to Andre Rancourt, CEO of Tetra Bio-Pharma, “After carefully studying the veterinary pet market and potential partnerships, the company decided to expand its development activities in order to tap into this lucrative market. In addition, Tetra is very fortunate to have Dr. Chamberland who has considerable experience navigating the regulatory affairs in the veterinary industry.”

Tetra had announced the successful completion of several corporate milestones associated with the development of its prescription drug products. These announcements lead to discussions with veterinary specialists who expressed the need for novel cannabinoid therapies for pets.

Tetra will create a Veterinary Advisory board consisting of veterinary specialists in the fields of ophthalmology, oncology and pain. This board of veterinary experts will help guide the development to ensure that the products target unmet veterinary needs for domestic animals. Tetra will use the veterinary drug development program to expand its potential revenues from the sales of a drug product in both the human and pet drug markets. The corporation will also establish partnerships with pharmaceutical companies specialized in the sale and distribution of veterinary products.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com